<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504829</url>
  </required_header>
  <id_info>
    <org_study_id>LCP-AtorFen-2001</org_study_id>
    <nct_id>NCT00504829</nct_id>
  </id_info>
  <brief_title>Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia</brief_title>
  <official_title>A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloxis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a
      combination of atorvastatin and fenofibrate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, 12 week study with a 52-week open-label
      follow-up to evaluate the safety and efficacy of LCP-AtorFen (the combination of atorvastatin
      and fenofibrate) in the treatment of hyperlipidemia.

      After a wash-out phase, eligible patients will be randomized on a 1:1:1 ratio to either
      LCP-AtorFen, atorvastatin or fenofibrate for 12 weeks. After the completion of the 12-week
      phase, all eligible patients will be offered to receive open-label LCP-AtorFen for another 52
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objectives of the study are to assess the non-HDL cholesterol and triglyceride lowering efficacy as well as the HDL cholesterol increasing efficacy of LCP AtorFen versus atorvastatin.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of the study are to assess the non-HDL and LDL cholesterol lowering efficacy as well as the HDL cholesterol increasing efficacy of LCP-AtorFen versus fenofibrate.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCP-AtorFen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fenofibrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCP-AtorFen</intervention_name>
    <description>anti-dyslipidemia</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>anti-dyslipidemia</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>anti-dyslipidemia</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of dyslipidemia (non-HDL-C &gt;130 mg/dL and Triglycerides &gt; or equal to 150
             mg/dL and &lt; or equal to 500 mg/dL).

          2. Subject may be currently on a statin or other lipid-lowering therapy but must be
             willing and able to washout for 8 weeks if on a fibrate or high-dose niacin, 6 weeks
             if on a statin or low-dose niacin per day, or 4 weeks if on a bile acid sequestrant,
             ezetimibe, or &gt;1000 mg of fish oil per day.

          3. Other inclusion criteria might apply

        Exclusion Criteria:

          1. TGs &gt; 500 mg/dL.

          2. History of coronary heart disease (CHD), transient ischemic attacks, stroke or
             revascularization procedure in the six months prior.

          3. Presence of an aortic aneurysm or resection of an aortic aneurysm within six months.

          4. Poorly controlled diabetes mellitus (glycosylated hemoglobin &gt;8.0% )or diabetes
             mellitus requiring insulin therapy.

          5. Known lipoprotein lipase impairment or deficiency or Apo C-II deficiency or familial
             dysbetalipoproteinemia.

          6. History of pancreatitis.

          7. Known allergy or sensitivity to statins or fibrates.

          8. Poorly controlled hypertension.

          9. Other exclusion criteria might apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Geohas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis McCluskey, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry Geisberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chivers Woodruff, Jr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Noss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Reynolds, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Zavoral, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall Severance, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Halpern, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Murray, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne Larson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Radiant Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Howards, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Affiliated Research Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Strout, MD</last_name>
    <role>Study Director</role>
    <affiliation>Coastal Carolina Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Kipnes, MD</last_name>
    <role>Study Director</role>
    <affiliation>Diabetes and Glandular Research Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, 515 N State Street, Suite 2700</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lifecyclepharma.com</url>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>April 11, 2008</last_update_submitted>
  <last_update_submitted_qc>April 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2008</last_update_posted>
  <keyword>LCP-AtorFen</keyword>
  <keyword>Non-HDL cholesterol</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>HDL cholesterol</keyword>
  <keyword>LDL cholesterol</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 18, 2014</submitted>
    <returned>December 30, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

